Peptide Comparison
Cerebrolysin vs Dihexa
Editorial breakdown of mechanism, evidence, decision criteria, and the misconceptions worth calling out.
Depends on goal
Both are described as cognitive compounds, and the evidence behind them fails in opposite directions. Cerebrolysin is a prescription medicine in more than 50 countries with randomized trials behind it, and the 2023 Cochrane review of those trials found no benefit on all-cause death in acute ischemic stroke plus a possible increase in non-fatal serious adverse events. Dihexa has no published human trial of any kind. Cerebrolysin is the only one of the two whose effects have been measured in people, which is why its negative result carries weight, and the absence of any result for Dihexa is not the better position. Consult a qualified clinician before any human use.
Evidence at a glance
FDA-approved Phase 3 Phase 2 / approved abroad Anecdotal + animal Preclinical / flagged
The actual difference
Cerebrolysin is a mixture of low molecular weight peptides derived from porcine brain, given by IV or IM infusion in 10 to 20 day courses. Dihexa is a single synthetic angiotensin IV analog taken orally, acting by potentiating hepatocyte growth factor signaling at the c-Met receptor. One is a biological extract with a regulatory file across Europe and Asia. The other is a defined small molecule sold as a research chemical, and the FDA compounding record lists it among substances nominated for the bulks lists and later withdrawn.
Which one to pick
Pick Cerebrolysin if
- The setting is a country where Cerebrolysin is an approved prescription medicine
- The reference question concerns stroke, dementia or traumatic brain injury, where the trials were actually run
- Supervised IV or IM administration is available
Pick Dihexa if
- The question is mechanistic rather than clinical, since the HGF and c-Met literature is the reason Dihexa is studied at all
- Preclinical synaptogenesis and dendritic spine formation are the endpoints of interest
- Oral or transdermal administration is the constraint
Avoid both if
- Cognitive decline is undiagnosed, since neither compound substitutes for a workup that identifies a treatable cause
- There is a personal or family history of cancer, given that Dihexa acts on the HGF and c-Met axis implicated in tumor invasion
- Pregnancy or planning pregnancy
Common confusions
- 'Approved in 50 countries means it works'. Not for the indication most often cited. The 2023 Cochrane review of Cerebrolysin in acute ischemic stroke covered 7 randomized trials and 1,773 participants and found moderate-certainty evidence of no effect on all-cause death, alongside a potential increase in non-fatal serious adverse events.
- 'Dihexa is seven orders of magnitude more potent than BDNF'. That figure comes from a preclinical assay of synaptogenic activity, not from a clinical outcome. Potency in an assay describes how little is needed to move that assay. It says nothing about whether the effect is useful or safe in a person.
- 'Both are nootropics, so they are interchangeable'. They share a category label and little else. One is a porcine brain extract given by infusion under supervision, the other is an oral synthetic acting on a growth factor pathway, and no study has compared them.
Side-by-side
| Cerebrolysin | Dihexa | |
|---|---|---|
| Class | Neurotrophic peptide mixture (porcine brain) | Angiotensin IV analog; HGF potentiator |
| Drug class | Cognitive | Cognitive |
| Mechanism | Mixture of low-MW peptides; neurotrophic factor-like activity on CNS neurons | Enhances HGF/c-Met signaling; promotes synaptogenesis and dendritic spine formation |
| Route | IV / IM | Oral / Transdermal |
| Half-life | Short (minutes-hours) | ~10 hrs |
| Dosage (research) | 5-30 mL IV/IM daily for 10-20 day courses | 8-45 mg oral daily (anecdotal) |
| Evidence tier | Approved in 50+ countries | Preclinical + Anecdotal |
| Research depth | 251 indexed | 75 indexed |
| Availability | Intl Prescription | Research Chemical |
| Reported risks | Injection site reactions; headache; dizziness | Very limited human data; theoretical tumor risk via HGF pathway |
Reported research data only. "Studied for" and "reported in literature" describe published research focus, not clinical recommendation. Most peptides catalogued here are not FDA-approved for human use.
Frequently asked questions
Should I pick Cerebrolysin or Dihexa?
Both are described as cognitive compounds, and the evidence behind them fails in opposite directions. Cerebrolysin is a prescription medicine in more than 50 countries with randomized trials behind it, and the 2023 Cochrane review of those trials found no benefit on all-cause death in acute ischemic stroke plus a possible increase in non-fatal serious adverse events. Dihexa has no published human trial of any kind. Cerebrolysin is the only one of the two whose effects have been measured in people, which is why its negative result carries weight, and the absence of any result for Dihexa is not the better position. Consult a qualified clinician before any human use.
What is the difference between Cerebrolysin and Dihexa?
Cerebrolysin is classed as Neurotrophic peptide mixture (porcine brain); Dihexa is classed as Angiotensin IV analog; HGF potentiator. Reported mechanism: Cerebrolysin, Mixture of low-MW peptides; neurotrophic factor-like activity on CNS neurons; Dihexa, Enhances HGF/c-Met signaling; promotes synaptogenesis and dendritic spine formation. Reported half-life: Cerebrolysin, Short (minutes-hours); Dihexa, ~10 hrs. Routes in published studies: Cerebrolysin, IV / IM; Dihexa, Oral / Transdermal.
Which has stronger evidence, Cerebrolysin or Dihexa?
Cerebrolysin has the stronger evidence base on PeptideHelper.org's five-step evidence scale, which runs from preclinical to FDA-approved. Cerebrolysin is graded Approved in 50+ countries, with 15 cited sources on its reference page and 251 indexed studies. Dihexa is graded Preclinical + Anecdotal, with 2 cited sources on its reference page and 75 indexed studies.
Which is more accessible, Cerebrolysin or Dihexa?
Neither Cerebrolysin nor Dihexa is an FDA-approved drug. Catalog status: Cerebrolysin, Intl Prescription; Dihexa, Research Chemical. Dihexa's nomination for FDA's bulk-substance lists was flagged by FDA and then withdrawn.
Are Cerebrolysin and Dihexa ever combined?
Cerebrolysin and Dihexa appear together in no stack catalogued on PeptideHelper.org, and the interaction engine raises no flag for the pair.
Open the PeptideHelper.org compare tool to add more compounds to this side-by-side and filter by evidence tier interactively.
Loading interactive view…